<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2387</td>
<td>Selected Articles from This Issue</td>
<td></td>
</tr>
<tr>
<td>2389</td>
<td>Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success</td>
<td>Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Houston, Jamie L. Studts, and Laura D. Scherer</td>
</tr>
<tr>
<td>2396</td>
<td>The National Cancer Institute Early Detection Research Network: Two Decades of Progress</td>
<td>Robert C. Bast Jr and Sudhir Srivastava</td>
</tr>
<tr>
<td>2401</td>
<td>The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers</td>
<td>Sudhir Srivastava and Paul D. Wagner</td>
</tr>
<tr>
<td>2411</td>
<td>Biomarkers for Lung Cancer Screening and Detection</td>
<td>Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash</td>
</tr>
<tr>
<td>2416</td>
<td>Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation</td>
<td>Maria Farooq and James G. Herman</td>
</tr>
<tr>
<td>2423</td>
<td>Lung Cancer and Immunity Markers</td>
<td>Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett</td>
</tr>
<tr>
<td>2441</td>
<td>Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia</td>
<td>Joshua D. Cohen, Brenda Diergaarde, Nickolas Papadopoulos, Kenneth W. Kinzler, and Robert E. Schoen</td>
</tr>
<tr>
<td>2454</td>
<td>Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review</td>
<td>Michael A. Liss, Robin J. Leach, Martin G. Sandy, and Oliver J. Semmes</td>
</tr>
<tr>
<td>2463</td>
<td>The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment</td>
<td>Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman</td>
</tr>
<tr>
<td>2475</td>
<td>Autoantibodies in Early Detection of Breast Cancer</td>
<td>Femina Rauf, Karen S. Anderson, and Joshua LaBaer</td>
</tr>
<tr>
<td>2486</td>
<td>Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers</td>
<td>William M. Grady, Ming Yu, Sanford D. Markowitz, and Amitabh Chak</td>
</tr>
<tr>
<td>2495</td>
<td>Biomarkers for the Early Detection of Hepatocellular Carcinoma</td>
<td>Nehar D. Parikh, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok</td>
</tr>
<tr>
<td>2513</td>
<td>Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN</td>
<td>Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrmann, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singh, Randall E. Brand, Anirban Maitra, and Brian B. Haab</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2524</td>
<td>Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network</td>
<td>Harvey I. Pass, Marjan Alimi, Michele Carbone, Haining Yang, and Chandra M. Goparaju</td>
</tr>
<tr>
<td>2541</td>
<td>The Potential of Circular RNAs as Cancer Biomarkers</td>
<td>Jason R. Brown and Arul M. Chinnaiyen</td>
</tr>
<tr>
<td>2556</td>
<td>Radiomics Improves Cancer Screening and Early Detection</td>
<td>Robert J. Gillies and Matthew B. Schabath</td>
</tr>
<tr>
<td>2568</td>
<td>Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA</td>
<td>Annie H. Ren, Clare A. Fiala, Eleftherios P. Diamandis, and Vathany Kulasingam</td>
</tr>
<tr>
<td>2575</td>
<td>Adding Rigor to Biomarker Evaluations—EDRN Experience</td>
<td>Ziding Feng and Margaret S. Pepe</td>
</tr>
<tr>
<td>2591</td>
<td>Premature Years of Life Lost Due to Cancer in the United States in 2017</td>
<td>Minkyo Song, Allan Hildesheim, and Meredith S. Shiels</td>
</tr>
<tr>
<td>2599</td>
<td>Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach</td>
<td>Kemal Caglar Gogebakan, Elizabeth G. Berry, Alan C. Geller, Kemal Sonmez, Sancy A. Leachman, and Ruth Etzioni</td>
</tr>
<tr>
<td>2617</td>
<td>Associations of Leisure-Time Physical Activity and Television Viewing with Life Expectancy Cancer-Free at Age 50: The ARIC Study</td>
<td>Carmen C. Cuthbertson, Hazel B. Nichols, Xianming Tan, Anna Kucharska-Newton, Gerardo Heiss, Corinne E. Joshu, Elizabeth A. Platz, and Kelly R. Evenson</td>
</tr>
<tr>
<td>2626</td>
<td>Community-Acquired Escherichia coli Bacteremia after Age 50 and Subsequent Incidence of a Cancer Diagnosis: A Danish Population-Based Cohort Study</td>
<td>Kirstine K. Sogaard, Katalin Veres, Christina M.J.E. Vandenbroucke-Grauls, Jan P. Vandenbroucke, Henrik T. Sørensen, and Henrik C. Schønheyder</td>
</tr>
<tr>
<td>2633</td>
<td>Low Levels of Alcohol Consumption and Risk of Intestinal Metaplasia: A Cohort Study</td>
<td>Kyunggeun Kim, Yousoo Chang, Jiin Ahn, Hyo-Joon Yang, and Seungho Ryu</td>
</tr>
<tr>
<td>2659</td>
<td>HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study</td>
<td>Christina Carlander, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Mensor Dzabic, Philippe Wagner, Aylin Yilmaz, Kristina Elfgen, Anders Sönnerborg, Pär Sparén, and Joakim Dillner</td>
</tr>
<tr>
<td>2662</td>
<td>Association between Receipt of Guideline-Concordant Lung Cancer Treatment and Individual- and Area-Level Factors: A Spatio-Temporal Analysis</td>
<td>Win Wah, Rob G. Stirling, Susannah Ahern, and Arul Earnest</td>
</tr>
<tr>
<td>2669</td>
<td>A Large Cohort Study of Body Mass Index and Pancreatic Cancer by Smoking Status</td>
<td>Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Alpa V. Patel, W. Dana Flanders, and Susan M. Gapstur</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2693</td>
<td>Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp</td>
<td>Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O'Connell, Mingyang Song, Kana Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor</td>
</tr>
<tr>
<td>2702</td>
<td>Evaluation of Circulating Tumor DNA for Methylated BCA11 and IKZF1 to Detect Recurrence of Stage II/III Colorectal Cancer (CRC)</td>
<td>Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marisa Hill, Iftekhar Khan, Samith T. Kochuparambil, Susan E. Lyons, James Orsini Jr, Susanne K. Pedersen, Bruce Robb, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young</td>
</tr>
<tr>
<td>2740</td>
<td>The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology</td>
<td>Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, "Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review," by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.
Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/29/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/29/12.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.